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The use of cancer chemotherapy and hyperthermia as part of a surgical procedure in the management of patients with peritoneal
carcinomatosis has gained prominence in recent years with selected patients showing beneﬁt. Patients with peritoneal surface
malignancy following cancer resection were treated with intraperitoneal hyperthermic (41.5–42.5◦C) cisplatin and doxorubicin
combined with the infusion of systemic ifosfamide chemotherapy. The concentrations of ifosfamide and 4-hydroxyifosfamide
were determined in plasma, peritoneal ﬂuid, urine, and when possible, within small tumor nodules less than 1cm. Plasma
concentrations of ifosfamide exceeded peritoneal ﬂuid levels of ifosfamide during the 90 minutes of chemotherapy infusion.
Both ifosfamide and 4-hydroxyifosfamide could be recovered from peritoneal tumor nodules throughout the 90 minutes of
ifosfamide continuous infusion and exceeded plasma concentrations. 4-Hydroxyifosfamide within peritoneal surface cancer
nodules suggested a favorable pharmacologic endpoint in the study of ifosfamide administered in the operating room.
1.Introduction
The use of intraoperative systemic chemotherapy to target
peritonealcarcinomatosisinpatientstreatedwithcytoreduc-
tive surgery and hyperthermic intraperitoneal chemotherapy
was ﬁrst explored by Elias and coworkers [1]. With this reg-
imen combining intravenous 5-ﬂuorouracil with intraperi-
toneal oxaliplatin, they reported a median survival of 62.7
months in a selected group of patients with carcinomatosis
from colon cancer [2]. This result was compared to matched
controlpatientstreatedwithmodernsystemicchemotherapy
resulting in a median survival of 23.9 months (P<0.05) [2].
The concept of heat targeting of systemic chemotherapy to
cancerous tissue has been used successfully in other disease
states. Schlemmerand coworkers in a randomized controlled
study determined the response of retroperitoneal sarcoma
to systemic ifosfamide with and without the addition of
deep hyperthermia [3]. Both the sarcoma response and the
survival of patients were improved by adding hyperthermia.
Ifosfamide may be an important drug for clinical trials
that evaluate the possible beneﬁts of heat targeting for
chemotherapy. It is one of four drugs that show true
heat synergy, with 5 to 10 times the duration of tumor
control with 41.5◦Ch e a ta sc o m p a r e dt on o r m a lt e m p e r -
atures [4]. In this paper we build on the data provided
by Zylberberg and colleagues on the use of intravenous
ifosfamide and intraperitoneal cisplatin for the management
of peritoneal surface malignancy, especially for ovarian
carcinomatosis and peritoneal mesothelioma [5]. Moderate
doses of systemic ifosfamide were used simultaneously with
intraperitoneal heat for 90 or 150 minutes. The peritoneal
surfaces were maintained at 41.5–42.5◦C using a large vol-
ume of hyperthermic intraperitoneal chemotherapy solution
and an external heater circulator [5–7]. The pharmacology
of systemic administered intraoperative ifosfamide and its
active metabolite, 4-hydroxyifosfamide, is the focus of this
paper. Before a clinical trial with survival as an endpoint can
be developed, strong pharmacologic support for this method
of treatment is required. The pharmacologic endpoint of
these treatment protocols is the demonstration of the active
form of this drug, 4-hydroxyifosfamide, within the nodules
of the peritoneal carcinomatosis. Also, a precise quantitation
of adverse events associated with the management is needed
before further applications of this approach can be contem-
plated.2 International Journal of Surgical Oncology
2.MaterialsandMethods
At the Washington Cancer Institute, 16 patients with peri-
toneal carcinomatosis were included in this study. Patients
on whom these pharmacologic studies were performed had
a progression of peritoneal carcinomatosis from gynecologic
cancer (4), colon (2), gastric (1), appendix (1), or diﬀuse
malignant peritoneal mesothelioma (8).Institutional Review
Board approval was obtained to collect and statistically
analyze data. Patient accrual was between July 1, 2007
and July 31, 2009. The goal of cytoreductive surgical
treatment was to reduce the intra-abdominal and pelvic
tumor volume to a cellular level [6–8]. Following this
surgical event, the edges of the abdominal incision were
elevated to create a reservoir within the abdominal and
pelvic space. A large volume (1.5liters/m2) of chemotherapy
solution containing cisplatin (50mg/m2)a n dd o x o r u b i c i n
(15mg/m2) was instilled. In two patients with prior adverse
reaction to cisplatin, mitomycin C at 15mg/m2 was used
with doxorubicin. The chemotherapy was administered in
a 1.5% dextrose peritoneal dialysis solution and maintained
by an external heater circulator (Belmont Medical Devices,
Billerica, MA, USA) at 41.5–42◦C for 90 minutes. The heated
chemotherapy solution was uniformly distributed with the
surgeon’s double-gloved hand. Fifteen minutes prior to
ifosfamide continuous infusion sodium-2-mercaptoethane
sulfonate (Mesna) at 260mg/m2 was administered intra-
venously as a bolus in 100mL of 0.9% sodium chloride.
Mesna was used to protect against hemorrhagic cystitis;
it was repeated at 4 and 8 hours. At the initiation of
the intraperitoneal chemotherapy treatments, the ifosfamide
(1,300mg/m2) in one liter of normal saline was started as
a continuous infusion at a constant rate over 90 minutes.
Prior to the initiation of all chemotherapy treatments, small
samples (each approximately one mL) of the intraperitoneal
chemotherapy solution and the ifosfamide solution were
taken as reference samples. Also samples of blood, urine, and
tumor nodules were taken prior to initiation of chemother-
apy treatments. These were used for preparation of quality
control samples. After initiation of chemotherapy, samples
of blood, peritoneal ﬂuid, and urine were taken at 15-
minute intervals for the ﬁrst 60 minutes and then at 30-
minute intervals. In some patients, small tumor nodules
(0.5–2cm) were present on the small bowel or small bowel
mesenterieswhichweremarkedduringcytoreduction.These
nodules were harvested at 15-minute intervals during the
hyperthermic intraperitoneal chemotherapy using curved
Mayo scissors. At the end of the procedure, all tumor
nodules had been accounted for. These tumor nodules
were histopathologically conﬁrmed as being malignant. In 4
patients, the sample collection continued for an additional
hour after the ifosfamide infusion was complete. The volume
of urine was monitored at 15-minute intervals. If core
temperatures reached 39◦C, the heating of the chemotherapy
solution was reduced.
2.1. Processing and Storage of Samples Obtained in the Oper-
ating Room. All samples collected in the operating room
were immediately placed on ice until processing. Processing
was as outlined by Kerbusch et al. [9]. Blood and peritoneal
ﬂuid samples were centrifuged at 3,000rpm for 10 minutes.
The resulting plasma and supernatant from peritoneal ﬂuid
along with urine samples were transferred to screw-capped
polypropylene tubes for storage at −20◦C. Tissue samples
weredriedofallsurfacemoistureusingabsorbentgauzepads
and placed in screw-capped polypropylene vials for storage
at −20◦C. These samples untreated by semicarbazide were
subsequently used for ifosfamide analysis.
2.2. Semicarbazide Stabilization of 4-Hydroxyifosfamide with-
in Samples Obtained in the Operating Room. Prior to storage
a 500-microliter sample of each biological ﬂuid (plasma,
peritoneal ﬂuid, and urine) was transferred to a small screw-
capped vial containing 50 microliters of a 2M solution
of semicarbazide (pH 7.4). Vials were tightly capped and
thoroughly mixed on a Vortex mixer for approximately
one minute. For quality control, a 450-microliter sample of
plasma taken prior to administration of chemotherapy was
treated with 50 microliters of a known concentration of 4-
hydroxyifosfamide·semicarbazide (4-OHIF·SCZ) prepared
from 4-hydroperoxyifosfamide and semicarbazide [10]. A
small nodule (approximately 50mg) from each tissue sample
was accurately weighed and homogenized in 450 microliters
of 0.5M NaH2PO4 (pH 7.4) in a screw-capped vial. Each
homogenate was then treated with 50 microliters of semi-
carbazide and mixed as with the biological ﬂuid samples. A
tissue control sample was prepared by homogenizing a small
(50mg) tumor nodule harvested prior to administration of
chemotherapyin450microlitersof0.5MNaH2PO4 towhich
50microlitersofaknownconcentrationof4-OHIF·SCZwas
added. All samples were then stored at −20◦C until HPLC
analysis. All HPLC analyses were performed within 48 hours
of time of storage.
2.3. Preparation of Samples for HPLC Analysis
2.3.1. Ifosfamide Assay. Ifosfamide levels were determined
using a modiﬁed version of the procedure described by
Margison et al. [11]. All samples were thawed at room
temperature prior to HPLC analysis. Peritoneal ﬂuid and
urine samples were diluted appropriately with a mobile
phase. A 3x to 5x dilution was necessary for peritoneal
ﬂuid samples, while urine dilutions ranged from 5x to 15x.
After thorough mixing the resulting solutions were ﬁltered
through 0.45 micron syringe ﬁlters prior to HPLC injection.
For plasma samples, a 500-microliter sample was mixed
with 500 microliters of 0.1N sodium hydroxide solution in
a screw-capped polypropylene centrifuge tube. A 5-milliliter
aliquot of a solution of 25% isopropanol in chloroform
was then added, and the mixture was thoroughly mixed
on a vortex mixer for approximately 2 minutes. After
centrifugation at 3000rpm for 10 minutes, the upper layer
was discarded and the lower layer was carefully removed
and transferred to a clean polypropylene centrifuge tube and
evaporated to dryness under a stream of N2 at 39◦C. The
resulting residue was dissolved in an appropriate volume
of mobile phase (2x to 3x) and ﬁltered through a 0.45-
micron syringe prior to HPLC injection. For quality control,International Journal of Surgical Oncology 3
a 500-microliter sample of “control” plasma with a known
concentration of ifosfamide was included in each assay.
Tumor nodules were again dried of surface moisture
before processing for ifosfamide assay. A small tumor nodule
(approximately100mg)wasaccuratelyweighedthenminced
in 150 microliters of 0.1N NaOH before being homogenized
in 2.5mL of 25% isopropyl alcohol in chloroform. The
homogenate was transferred to a 15mL polypropylene cen-
trifugetubeandcentrifugedat3,000rpmfor10minutes.The
lower organic phase was transferred to a clean polypropylene
t u b ea n de v a p o r a t e dw i t ha nN 2 stream as with the plasma,
peritonealﬂuid,andurine.Theresiduewasdissolvedin1mL
mobile phase and ﬁltered through a 0.45-micron syringe
ﬁlter. For quality control, a 100mg tumor nodule taken
prior to the administration of ifosfamide was minced in 150
microlitersof0.1NNaOHwhichcontainedaknownamount
ofifosfamideandprocessedasabove.A50-microliteraliquot
of each sample was injected for HPLC analysis.
2.3.2. 4-Hydroxyifosfamide Assay. 4-Hydroxyifosfamide lev-
els were determined in the derivatized samples using a
slightly modiﬁed version of the procedure described by
Kerbusch and colleagues [10]. Brieﬂy, all samples were
thawed at room temperature. Peritoneal ﬂuid samples and
urine samples were diluted appropriately with the mobile
phase and ﬁltered through 0.45-micron syringe ﬁlters prior
to HPLC injection.
The plasma derivatives and the 4OHIF·SCZ plasma
control sample were extracted with a 10x volume of acetoni-
trile in screw-capped polypropylene centrifuge tubes. After
centrifugation the clear acetonitrile extracts were transferred
to clean polypropylene tubes and evaporated to dryness
under a constant stream of N2 at 39◦C. The residues were
each dissolved in 1mL of the mobile phase and ﬁltered
through a 0.45-micron syringe ﬁlter before HPLC injection.
The homogenates from the tumor nodule derivatives
along with the 4-OHIF·SCZ control sample were thor-
oughlymixed againbeforeprocessing. Eachhomogenatewas
extracted with 5 milliliters of ethyl acetate in a screw-capped
polypropylene centrifuge tube. After centrifugation the
organicsupernatantwastransferredtoacleanpolypropylene
tube and evaporated to dryness under a steady stream of N2
at 39◦C. The residue was dissolved in 1mL of the mobile
phaseandﬁlteredthrougha0.45-micronsyringeﬁlterbefore
HPLC injection. A 50-microliter aliquot of each sample was
injected for HPLC analysis.
2.4. Ifosfamide as an Internal Standard. For each patient a
reference sample of ifosfamide was obtained in the operating
room directly from the bag of chemotherapy solution. This
was used to prepare a standard curve by which all other
samples taken from the patient were evaluated. It was also
used for the preparation of quality control samples.
2.5. HPLC System for Ifosfamide and 4-Hydroxyifosfamide.
Brieﬂy, the HPLC system consisted of a Shimadzu LZ7A
instrument equipped with the SPD-6AV (UV-VIS) Detector
set at 190nm and AC-R6A Chromatopac Data Processor
(Shimadzu Instruments, Columbia, MD, USA). Chromato-
graphicseparationwasaccomplishedonaC8ReversedPhase
Column (Varian Incorporated, 25200 Commerce Center
Drive, Lake Forest, CA, USA). The mobile phase for ifos-
famide consisted of 30% acetonitrile in a 0.01M phosphate
buﬀer (pH 6.5) at a ﬂow rate of 1.5mL/min.
Concentrations of 4-hydroxyifosfamide were determined
using a modiﬁed version of the HPLC system as described
by Kerbusch and colleagues [9, 10]. The HPLC system was as
described for ifosfamide. The mobile phase consisted of 24%
acetonitrilein0.025Mpotassiumdihydrogenphosphatewith
0.1% triethylamine at a ﬂow rate of 0.9mL/min. The SPD-
6AV (UV-VIS) Detector was set at 230nm.
2.5.1. Data Analysis and Presentation. The concentration
of ifosfamide and 4-hydroxyifosfamide in tumor nodules
(Ctumor nodule) was determined by dividing the concentration
of the drug in the tumor nodule homogenate (micrograms
of drug per milliliter of homogenate) by the concentration of
t i s s u ei nt h et u m o rn o d u l eh o m o g e n a t e( g r a m so ft i s s u ep e r
milliliter of homogenate):
Ctumor nodule = micrograms(drug) ×milliliters(homogenate)
−1,
grams(tissue) × milliliters(homogenate)
−1
= micrograms(drug),
grams(tissue).
(1)
This expression of the drug concentration in tumor
nodules represents the closest equivalence to the drug con-
centration in the biologic ﬂuid samples (peritoneal ﬂuid,
plasma, and urine). It is based on the assumption that one
gram of tissue has a volume of approximately one cubic
centimeter. The micrograms/grams was presented in the
ﬁgures as micrograms/milliliter.
AlldatawascompiledandanalyzedusingMicrosoftExcel
(Microsoft Corporation, Redmond, WA, USA). Data were
displayedasmean±1standarddeviation.Theareaunderthe
curve data was determined using GraphPad Prism Software
(GraphPad Software Inc., La Jolla, CA, USA).
2.5.2. Adverse Events. The database was prospectively com-
pleted on individual patients by physician’s assistants (RA
and GE) as the hospital discharge summary was being
dictated. These records were then reviewed by the senior
attending or other attending surgeon. Data were entered
into the computer by a nurse. The database was constructed
speciﬁcally to evaluate patients treated for peritoneal surface
malignancy [12]. It consisted of 47 adverse events arranged
in 8 categories by organ system. The categories and a list of
adverse events that were scored for each patient are listed in
Table 1. For each adverse event a grade was assigned. For
a grade I adverse event, the diagnosis was established, but
no treatment was required. For grade II, the adverse event
requiredmedicaltreatmentforaresolution.ForgradeIII,the
adverse event was potentially serious but was resolved con-
servatively,oftenwithaninvasiveinterventionforresolution.4 International Journal of Surgical Oncology
Table 1: Postoperative morbidity-mortality database in patients
withperitonealsurfacemalignancytreatedbycytoreductivesurgery,
hyperthermic intraperitoneal cisplatin and doxorubicin, and simul-
taneous intravenous ifosfamide. Eight categories of events and 47
adverse outcomes were scored.
Category Adverse event
Gastrointestinal
Anastomotic failure
Fistula
Pancreatic ﬁstula
Pancreatitis
Bile leak from liver surface
Hartmann pouch blowout
Enterostomy tube complication
Oral pain/ulceration
Nausea/vomiting
Diarrhea
Ascites
Other
Pulmonary
Respiratory distress
Pleural eﬀusion
Pneumonia
ARDS
Chest tube removal
Other
Intravenous catheter
status
Line sepsis
Line thrombosis
Insertion pneumothorax
Total parenteral nutrition intolerance
Other
Cardiovascular
Rhythm
Hypotension
Ischemia
Pulmonary embolism
Thrombophlebitis
Venous thrombosis
Pulmonary edema
5-Fluorouracil cardiac toxicity
Other
Genitourinary
Urinary tract infection
Urine leak
Other
Hematological
WBC
Platelets
Postoperative hemorrhage
Units of fresh-frozen plasma
Other
Neurotoxicity
State of communication
Orientation/intellect
Stroke
Other
Infection
Intra-abdominal infection
Wound infection
Other
ARDS: acute respiratory distress syndrome; WBC: white blood cell count.
This was often a computed tomographic- or ultrasound-
guided therapeutic intervention. For grade IV, the adverse
event required deﬁnitive urgent intervention, often a return
to the operating room or to the surgical intensive care unit.
A grade V adverse event led to the patient’s death.
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Figure 1: Plasma, peritoneal ﬂuid, and urine concentrations of
ifosfamide during a 90-minute continuous infusion. The total
quantity of ifosfamide in mg excreted in the urine is presented at
the bottom. The median concentration of plasma, peritoneal ﬂuid
and urine ifosfamide is shown separately.
3. Results
3.1. Ifosfamide Concentrations in Plasma, Peritoneal Fluid,
and Urine. Figure 1 shows the ifosfamide concentrations in
blood, peritoneal ﬂuid, and urine for 6 patients treated with
a 90-minute ifosfamide infusion and 90 minutes of heated
intraoperative intraperitoneal chemotherapy (HIPEC). The
peritoneal ﬂuid levels rapidly increased; however, in all
patients peritoneal ﬂuid remained lower than the plasma
ifosfamide levels throughout the 90-minute infusion. A large
quantity of the ifosfamide was excreted unchanged in the
urine. The median concentration of ifosfamide in plasma,
peritoneal ﬂuid, and urine is shown separately; these data are
the median values of all concentrations over 90 minutes.
3.2. 4-Hydroxyifosfamide Concentrations in Plasma, Peritone-
al Fluid, and Urine. Figure 2 shows the 4-hydroxyifosfamide
concentrations in plasma, peritoneal ﬂuid, and urine for 6
patients treated with a 90-minute ifosfamide infusion and 90
minutesofHIPEC.Whenameanconcentrationofperitoneal
ﬂuid and plasma was plotted, the concentrations in these
two body compartments continued at similar levels over
the 90 minutes. Urine excretion continued to be large for
the entire 90 minutes showing that large amounts of the
active metabolite of this chemotherapy agent was present
unchanged in the urine.
3.3. Ifosfamide and 4-Hydroxyifosfamide Concentrations over
150 Minutes. Figure 3 shows the plasma, peritoneal ﬂuid,
and urine concentrations in 10 patients. The ifosfamide
continuous infusion was used over the 90 minutes in theseInternational Journal of Surgical Oncology 5
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Figure 2: Plasma, peritoneal ﬂuid, and urine concentrations of 4-
hydroxyifosfamide over a 90-minute infusion. The total quantity of
4-hydroxyifosfamide in mg excreted in the urine is presented at the
bottom.
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Figure 3: Plasma, peritoneal ﬂuid, and urine concentrations of
ifosfamide and 4-hydroxyifosfamide over a 90-minute infusion and
60-minute period of observation.
patients; however, the volume of intraperitoneal chemother-
apy solution and the heating of this chemotherapy solution
were maintained for an additional hour for a total of 150
minutes. Elevated concentrations of plasma ifosfamide as
compared to peritoneal ﬂuid ifosfamide continued through-
out the 90-minute infusion. However, during the 90-minute
to 150-minute period, the concentration in the peritoneal
ﬂuid and plasma equilibrated.
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Figure 4: Comparison of ifosfamide and 4-hydroxyifosfamide con-
centrations in tumor nodules and in plasma.
For 4-hydroxyifosfamide the plasma and peritoneal ﬂuid
levels were similar over the 150 minutes. The levels of drug
in these two compartments decreased minimally after the
infusion ceased at 90 minutes. A prolonged presence of 4-
hydroxyifosfamide in the plasma and in the peritoneal ﬂuid
is evident.
3.4. Comparisons of Ifosfamide and 4-Hydroxyifosfamide
Concentrations in Tumor Tissue and in Plasma. Figure 4
shows the mean ifosfamide concentration in tumor nodules
harvested in 5 patients over 90 minutes. Also shown are
the mean concentrations in plasma. The concentrations in
tumor nodules were consistently elevated as compared to
the concentrations determined within the plasma for 60
minutes. Similar data were obtained in 4 of these 5 patients
for 4-hydroxyifosfamide. Levels of 4-hydroxyifosfamide in
tumor tissues were consistently greater than observed within
the plasma.
3.5. Four- and Eight-Hour Measurements of Ifosfamide and 4-
Hydroxyifosfamide. In 3 patients, blood and urine samples
were obtained at 4 and 8 hours after initiation of the
ifosfamide infusion. The mean ifosfamide concentration in
the plasma at 4 hours and 8 hours, respectively, was 27.4 ±
2.4µg/mL and 22.02 ± 0.8µg/mL. The mean concentration
in the urine at 4 hours and 8 hours, respectively, was 138.0 ±
85.7µg/mL and 58.45 ± 35.1µg/mL. Considerable quantities
of active drug remain in the plasma and urine of these
patients 8 hours following infusion of the chemotherapy.
The four-hour concentrations of 4-hydroxyifosfamide in
plasma and urine were also determined. The mean 4-
hydroxyifosfamide concentration in plasma at 4 hours was
0.06 ± 0.03µg/mL. The mean 4-hydroxyifosfamide in urine
at 4 hours was 3.4 ± 2.1µg/mL.
3.6. Adverse Events. The clinical features on these 16
patients treatedwith cytoreductivesurgeryandperioperative6 International Journal of Surgical Oncology
hyperthermic chemotherapy are listed in Table 2.T h e r e
were no abnormalities of BUN or creatinine prior to or
after the bidirectional chemotherapy treatments neither was
hematuria observed. Table 2 itemizes the adverse events that
were prospectively recorded. There were no mortalities, two
grade IV adverse events (13%), and no grade III events.
4. Discussion
4.1. Heat Targeting of Cancer Chemotherapy. Two decades
of research seeking the mechanisms for heat augmentation
of chemotherapy killing have been published [4, 13–21].
It is possible that improvements in the care of cancer
patients result with the concomitant use of heat and systemic
chemotherapy. Unfortunately, logistical problems with the
simultaneous administration of heat and chemotherapy
occur in most clinical situations. Schlemmer and colleagues
were able to overcome these logistical problems and com-
bined intravenous doxorubicin and ifosfamide with deep
hyperthermia for truncal sarcoma [3]. In a randomized
study they showed improved responses when heat was
added to the intravenous infusion of systemic chemotherapy.
Several groups showed that the intravesical instillation of
mitomycin C was more eﬀective when the chemotherapy
solution in the bladder was maintained at 43◦Ca sc o m p a r e d
to body temperature [21]. In the present study, systemic
ifosfamide was targeted to the peritoneal surface cancer
nodulesby ﬂooding theperitonealcavity witha largevolume
of heated peritoneal dialysis solution. Small tumor nodules
were heated to at least 41.5◦C. Larger tumor nodules would
be more resistant to heat penetration of the entire mass
of cancer. Using this technology the cytotoxic eﬀects of
ifosfamide are expected to be maximized within heated
peritoneal surface tumor nodules.
4.2. Rationale Supporting Bidirectional Intraoperative Chem-
otherapy. In this treatment strategy the bidirectional
(intraperitoneal and intravenous) administration of cancer
chemotherapymayprovideauniqueadvantagefortreatment
of carcinomatosis. The chemotherapy solution within the
abdomen contains cisplatin and doxorubicin. By simple
diﬀusion these two chemotherapy agents would enter the
tissue of small cancer nodules. High levels of doxorubicin
and cisplatin have been documented within peritoneal
surface cancer nodules [22, 23]. However, not only are these
intraperitonealchemotherapyagentsaugmentedbyheat,but
alsothe4-hydroxyifosfamideisheatedasitreachesthetumor
nodule from the bloodstream. Chemotherapy from both the
intraperitoneal and intravenous compartments converges
on the tissues at the interface of heated intraperitoneal ﬂuid
and peritoneal surface. These are the tissues that contain
peritoneal carcinomatosis or peritoneal mesothelioma nod-
ules.
4.3. Ifosfamide as a Prodrug. Ifosfamide is a diﬃcult drug
to study pharmacologically. Its anticancer eﬀects only occur
after the prodrug, ifosfamide, is metabolized in the liver
and red blood cells by the cytochrome system to 4-
hydroxyifosfamide. The active metabolite is unstable and
only exists for a few minutes within the plasma or within
the red blood cell. The larger standard deviations in 4-
hydroxyifosfamide levels in Figure 2 as compared to the data
of Figure 1 with ifosfamide may result from this instability.
The activity of ifosfamide cannot be studied in vitro because
the drug is not activated in the absence of metabolism. This
fact makes our pharmacologic in vivo studies of ifosfamide
even more important. We have been able to document the
presence of the active compound within the peritoneal ﬂuid
bathingsmallcancernodules.Wehavealsobeenabletoshow
that the active molecule, 4-hydroxyifosfamide, is present
within these small tumor nodules. This quantitation of 4-
hydroxyifosfamide is possible as a result of the stabilization
of the molecule with semicarbazide [9, 10].
4.4. Choice of Intravenous Ifosfamide to Augment Hyperther-
mic Intraperitoneal Chemotherapy. Ifosfamide is a broadly
active chemotherapy highly active in soft tissue sarcoma,
nonsmallcelllungcancer,andovariancancer[24].Itsunique
activity for use along with heated chemotherapy solutions
comes from a remarkable augmentation of cytotoxicity by
moderate heat. Urano et al. in a mouse foot-pad model
demonstrate a tumor growth rate to decrease by one-third
when ifosfamide was used at 41.5◦Ca so p p o s e dt or o o m
temperature [4]. In small tumor nodules that remain after
cytoreduction intraperitoneal heat should cause increased
cytotoxicity at the peritoneal surface in the absence of
increased systemic toxicity.
4.5. Ifosfamide as a Continuous Infusion. T h ei f o s f a m i d ei n
this study is delivered as a continuous infusion, and, there-
fore, these data are diﬀerent than our previous publications
using systemic 5-ﬂuorouracil [25]. With 5-ﬂuorouracil the
drug is administered as a bolus over 7 minutes. The blood
and peritoneal ﬂuid equilibrate within 15 minutes. However,
after equilibration, drug levels within the peritoneal ﬂuid
remain at a higher level than those in the plasma. If a
pharmacologic analysis of ifosfamide is performed after the
90minutesofcontinuousinfusion,thesamephenomenonof
more rapid metabolism in the peripheral blood as compared
to the peritoneal space is observed. The phenomenon does
not occur nearly so rapidly because the metabolism of ifos-
famide is slower than 5-ﬂuorouracil. These data show that
the method of administration of the intravenous drug (bolus
as compared to continuous infusion) may have a profound
eﬀect on the pharmacokinetics parameters measured in this
perioperative use of cancer chemotherapy.
4.6. Comparison of Plasma and Peritoneal Fluid Ifosfamide
and 4-Hydroxyifosfamide Concentrations. The plasma levels
of ifosfamide are always greater than the peritoneal ﬂuid
levels. Perhapsthis is caused by the continuous drug infusion
into the venous blood and its delay in distribution to the
peritoneal space. This would account for the persistent
higher levels of ifosfamide within the 90-minute infusion.
However, during the 90-minute to 150-minute period,International Journal of Surgical Oncology 7
Table 2: Clinical features and prospective morbidity-mortality assessment of 16 patients with peritoneal surface malignancy having cytore-
ductive surgery and perioperative hyperthermic chemotherapy.
Patient Gender/age Diagnosis Grade II morbidity Grade III morbidity Grade IV morbidity Mortality Current status
(months)
1 M/47 Appendix 0 0 0 0 DOD (9)
2 F/56 Papillary serous 0 0 0 0 AWD (26)
3 F/44 Papillary serous 0 0 Hyponatremia, return
to SICU 0 NED (31)
4 F/55 Papillary serous 0 0 0 0 NED (29)
5 M/19 Recurrent colon Postoperative bleeding 0 0 0 AWD (19)
6 M/54 DMPM Central line infection 0 0 0 AWD (20)
7 F/30 DMPM Urinary tract infection 0 Excessive ascites,
return to SICU 0 AWD (18)
8 F/61 Endometrial Urinary tract infection 0 0 0 DOD (6)
9 F/60 DMPM Pleural eﬀusion 0 0 0 AWD (18)
10 F/51 DMPM 0 0 0 0 NED (16)
11 M/54 DMPM Neuropraxia 0 0 0 NED (14)
12 M/47 Colon 0 0 0 0 AWD (14)
13 M/61 DMPM 0 0 0 0 AWD (14)
14 M/64 Gastric 0 0 0 0 DOD (6)
15 M/52 DMPM 0 0 0 0 NED (13)
16 M/58 DMPM 0 0 0 0 AWD (12)
DMPM: diﬀuse malignant peritoneal mesothelioma; DOD: died of disease; AWD: alive with disease; NED: no evidence of disease; SICU: surgical intensive
care unit.
the concentration in the peritoneal ﬂuid and plasma equi-
librated.
For 4-hydroxyifosfamide, the variability of levels in the
peritoneal ﬂuid versus plasma was evident by the wide stan-
dard deviations calculated. However, a prolonged presence
of 4-hydroxyifosfamide in the plasma and in the peritoneal
ﬂuid was evident.
4.7. Morbidity and Mortality. The morbidity and mortality
of this treatment plan are presented in Table 2.I tc o m -
pares favorably with the morbidity and mortality previ-
ously described for cytoreductive surgery with hyperthermic
intraperitonealchemotherapy[26–28].Previousstudieshave
documented that the major factor inﬂuencing morbidity
with cytoreductive surgery and perioperative hyperthermic
chemotherapy is the extent of surgery [29, 30]. In these two
patients the grade IV morbidity was related to the disease
process rather than the chemotherapy toxicities.
4.8. Prolonged Hyperthermia to Maximize Chemotherapy
Eﬀect. After the ﬁrst seven patients received a 90-minute
infusion of ifosfamide and 90 minutes of intraperitoneal
hyperthermia, we observed, by taking blood samples at
2.5 hours after the initiation of infusion, that high levels
of ifosfamide and 4-hydroxyifosfamide were maintained. It
became evident that prolonging the hyperthermia within the
peritoneal space would continue the cytotoxic eﬀects of the
cancer chemotherapy without any increase in its systemic
toxicity. Therefore, a 2.5-hour hyperthermia treatment to
maximize the eﬀects of heat should be considered to maxi-
mize cytotoxicity.
4.9. Variability of Plasma and Peritoneal Fluid Concentrations
of 4-Hydroxyifosfamide. In the monitoring of these patients,
the concentrations over 90 minutes of plasma ifosfamide
were always slightly increased over the peritoneal ﬂuid
ifosfamide concentrations. This observation occurred in
all 11 patients. However, with 4-hydroxyifosfamide, con-
siderable variation in the levels of plasma and peritoneal
ﬂuid hydroxyifosfamide occurred. Sometimes the plasma 4-
hydroxyifosfamide was considerably greater than that found
in the peritoneal ﬂuid. In other patients the reverse was
seen. Individual patient variations may account for these
diﬀerences including variable metabolism of ifosfamide to
4-hydroxyifosfamide, variable ascites accumulation during
the 90-minute infusion, and variable urine output of 4-
hydroxyifosfamide.
4.10. Long-Term Activity of Ifosfamide and 4-Hydroxyifos-
famide. In this study, in four patients we documented
the high levels of ifosfamide and the active molecule 4-
hydroxyifosfamide present long term in the blood of these
patients. This observation attests to the need for Mesna over
a long-time period when using ifosfamide.
4.11. Analogies to the Zylberberg Protocol. The treatment
strategy that has been employed in our studies is very
similar to that published by Zylberberg and colleagues8 International Journal of Surgical Oncology
for ovarian cancer [5]. His study showed excellent clinical
results when systemic ifosfamide infusion was combined
with intraperitoneal cisplatin. We modiﬁed his ifosfamide
regimen using an infusion over 90 minutes in the operating
room. The results that he has achieved with this bidirectional
chemotherapy administration (intravenous and intraperi-
toneal) at normothermic temperatures may be the best
long-term results with ovarian malignancy reported to date.
Our group is hopeful that modiﬁcation of his treatment
strategy through the use of heat targeting of the cytotoxic
eﬀects of 4-hydroxyifosfamide to peritoneal surfaces may
further beneﬁt patients with peritoneal carcinomatosis and
peritoneal mesothelioma.
4.12. Pharmacologic Limitations of the Current Study.
Although the ifosfamide levels in blood, peritoneal ﬂuid,
and urine could be veriﬁed through the use of a blank, this
was not true in the determination of 4-hydroxyifosfamide
levels. No standard molecule was available to add to normal
blood, peritoneal ﬂuid, and urine that would verify our
HPLC technology. The fact that 4-hydroxyifosfamide was
documented to be present within the cancer nodules is, in
and of itself, an important observation.
4.13. Clinical Limitations of the Current Study. These data
show a pharmacologic rationale for ifosfamide as a reason-
able addition to hyperthermic intraperitoneal chemotherapy
in an attempt to improve the eﬀects of the perioperative
treatments.However,thispharmacologicrationaleshouldbe
substantiated in clinical trials supporting the survival beneﬁt
of this pharmacologically engineered treatment protocols.
A phase II study of the individual diseases appropriate
for this approach needs to occur. The obvious choices for
these studies are stage III ovarian cancer and peritoneal
mesothelioma. Also, patients with sarcomatosis or a high
risk of sarcomatosis after primary cancer resection could
be considered for a treatment protocol similar to that
used in this study. Of course, if phase II data is favorable
and the morbidity and mortality stay within an acceptable
limit, prospective and randomized studies of patients with
peritoneal metastases from ovarian cancer and sarcoma
should be considered; also, peritoneal mesothelioma is an
ideal clinical setting.
5. Conclusion
A clear understanding of the pharmacology of perioperative
intraperitoneal hyperthermic chemotherapy combined with
systemic chemotherapy in the operating room may provide
important information for the design of an optimal treat-
ment for peritoneal surface malignancy. These data showed
thatasystemicdrug,ifosfamide,waspresentintheperitoneal
ﬂuid and in the tumor nodules in patients with peritoneal
carcinomatosis or peritoneal mesothelioma. These small
nodules in direct contact with the hyperthermic intraperi-
toneal chemotherapy solution may have marked augmen-
tation of the cytotoxicity of the systemic chemotherapy.
Ifosfamide may be an ideal drug for systemic administration
with local-regional heat because it is greatly augmented in its
eﬀects by moderate heat. Application of these treatments in
ovarian malignancy and peritoneal mesothelioma may be of
beneﬁt.
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